IPSC Stock — Century Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.86

Market cap

$336.8M

Cash

$119.7M

Enterprise value

$217.1M

Balance sheet

Cash	$119.7M
Debt	$0.0M
Net cash	$119.7M
Enterprise value	$217.1M
Basic shares	180.5M shares
Fully diluted shares	239.8M shares
Fully diluted market cap	$446.0M
Cash per share	$0.66

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IPSC daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 12 - Oct 24	CNTY-101	Phase 1	Systemic Lupus Erythematosus; Lupus Nephritis; Idiopathic Inflammatory Myopathies	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CNTY-813

Preclinical · Active Modality: cell therapy (iPSC-derived beta islet cell replacement)

Indications

Type 1 diabetes (T1D) (Preclinical)

Catalysts

— 2026

Status note Lead product candidate: iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0, designed to protect from T cell, NK cell and humoral immune rejection for durable glycemic control without chronic immunosuppression. In IND-enabling studies (announced Nov 2025). Preclinical data: restored normoglycemia maintained for over 4 months in a diabetic mouse model.

CNTY-308

Preclinical · Active Modality: cell therapy (iPSC-derived CD4+/CD8+ CAR-iT cell)

Target CD19

Indications

B-cell-mediated diseases (Preclinical)

Catalysts

— 2026

Status note CD19-targeted CD4+/CD8+ alpha-beta CAR-iT cell therapy engineered with Allo-Evasion 5.0, designed for off-the-shelf treatment of B-cell-mediated diseases. In IND-enabling studies; functionally comparable to primary T cells in preclinical testing.

CNTY-101

Phase 1 · Active Modality: cell therapy (iPSC-derived CAR-iNK cell)

Target CD19

Partnerships Phase 1/2 investigator-sponsored trial (CARAMEL) sponsored by Friedrich-Alexander University Erlangen-Nurnberg (Professors Georg Schett and Andreas Mackensen). BMS collaboration on iNK/iT programs terminated without cause Mar 2025.

Indications

SLE / lupus nephritis (Phase 1)
Idiopathic inflammatory myopathy (IIM) (Phase 1)
Diffuse cutaneous systemic sclerosis (DcSSc) (Phase 1)

Catalysts

— 2026

Status note First therapeutic candidate: off-the-shelf iPSC-derived CAR-iNK incorporating CD19 CAR, secreted IL15, EGFR safety switch and six precision edits (Allo-Evasion 1.0). Phase 1/2 CARAMEL IST currently enrolling and dosing patients with B-cell-mediated autoimmune diseases (SLE, lupus nephritis, IIM, DcSSc); initial data presented Dec 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CNTY-101
Lead indication	Systemic Lupus Erythematosus
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06255028	Phase 1	Active, not recruiting	Sponsor	IPSC	—	Systemic Lupus Erythematosus; Lupus Nephritis; Idiopathic Inflammatory Myopathies	—
NCT05768269	Not disclosed	Recruiting	Sponsor	IPSC	—	Hematological Malignancy; Solid Tumor Malignancy	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Century Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	8,695,652	no change	0.18%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

IPSC — Century Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders